Ochiai Takumi, Nishimura Kazuhiko, Noguchi Hajime, Kitajima Masayuki, Tsuruoka Yuko, Takahashi Yuka, Tsukada Akira, Watanabe Emiko, Nagaoka Isao, Futagawa Shunji
Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan.
J Surg Oncol. 2006 Jul 1;94(1):45-50. doi: 10.1002/jso.20553.
Phosphoribosylation of 5-fluorouracil (5-FU) is an essential step which leads to tumor growth inhibition and orotate phosphoribosyl transferase (OPRT) is the main enzyme that involves in this conversion of 5-FU to 5-fluorouridine monophosphate. This retrospective study was aimed to evaluate the correlation between tumor OPRT activity and the clinical outcome in colorectal cancer (CRC) patients treated by oral 5-FU-based adjuvant chemotherapy.
Surgical specimen was obtained from resectable 124 CRC patients who were subsequently treated by oral 5-FU-based adjuvant chemotherapy. OPRT activity in the extract of tumor tissue was enzymatically determined. The cut-off value of intratumor OPRT activity against disease free survival was determined by maximal chi2 method. The disease free survival and overall survival in each group were calculated using the Kaplan-Meier method.
Patients were divided into two groups by determined cut-off value of intratumor OPRT (0.147 nmol/min/mg protein) (high group: n = 102, low group: n = 22). Five-year DFS (P = 0.035) and OS (P = 0.020) were significantly better for high OPRT group.
This study demonstrated that an assay of tumor OPRT contributes to the determination of 5-FU-based adjuvant chemotherapy outcome and application in clinical practice should be included in tumor analysis prior to 5-FU-based adjuvant chemotherapy.
5-氟尿嘧啶(5-FU)的磷酸核糖基化是导致肿瘤生长抑制的关键步骤,而乳清酸磷酸核糖基转移酶(OPRT)是参与5-FU转化为5-氟尿苷单磷酸的主要酶。本回顾性研究旨在评估肿瘤OPRT活性与接受口服5-FU辅助化疗的结直肠癌(CRC)患者临床结局之间的相关性。
从124例可切除的CRC患者中获取手术标本,这些患者随后接受口服5-FU辅助化疗。通过酶法测定肿瘤组织提取物中的OPRT活性。采用最大卡方检验确定肿瘤内OPRT活性对无病生存期的临界值。每组的无病生存期和总生存期采用Kaplan-Meier法计算。
根据肿瘤内OPRT的临界值(0.147 nmol/分钟/毫克蛋白)将患者分为两组(高值组:n = 102,低值组:n = 22)。OPRT高值组的五年无病生存期(P = 0.035)和总生存期(P = 0.020)显著更好。
本研究表明,肿瘤OPRT检测有助于确定基于5-FU的辅助化疗结局,在基于5-FU的辅助化疗前,应将其应用纳入肿瘤分析的临床实践中。